Drs. Chih-ho Hong and Gurbir Dhadwal discuss 52-week efficacy results from the Phase 3 POETYK PSO-1 and POETYK PSO-2 trials as presented at the 30th EADV Congress [Video 5 min]

What impact will the novel oral therapy, deucravacitinib, have on the treatment landscape of patients with plaque psoriasis? Dr. Chih-ho Hong and Dr. Gurbir Dhadwal discuss the 52-week efficacy results from the Phase 3 POETYK PSO-1 and POETYK PSO-2 trials as presented at the 30th EADV Congress.


>> View the video [4 min 42 sec]

This video series was developed by a faculty of Canadian dermatologists from across Canada as part of the C2 Dermatology: Connect & Collaborate learning program. View all C2 Dermatology videos at psolve.org/c2-derm.

In compliance with Innovative Medicines Canada, this program is for Healthcare Professionals only, and is supported by Novartis Pharmaceuticals Canada.